Physician profile
Margaret Bailey
NPI 1518946433
$4,579.22
in general payments reported to CMS, 2019-2025
28 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $639 · 2021: $1,316 · 2022: $828 · 2023: $490 · 2024: $460 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113 · Education: $28.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,112.50 |
| Education | $28.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,560.48 | 2019-2025 | Skyrizi, Mavyret, Viberzi |
| Pfizer INC. | $541.05 | 2019-2025 | |
| Janssen Biotech, INC. | $377.93 | 2020-2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $315.04 | 2020-2024 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $274.23 | 2020-2024 | Entyvio |
| Ucb, INC. | $238.45 | 2019-2020 | |
| Gilead Sciences, INC. | $202.73 | 2019-2024 | |
| Braintree Laboratories, INC. | $112.50 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $111.98 | 2019-2024 | Clenpiq |
| Celgene Corporation | $100.73 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $84.94 | 2022-2023 | Dupixent |
| Intercept Pharmaceuticals, INC. | $83.74 | 2019-2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $76.60 | 2019-2022 | |
| Qol Medical, LLC | $67.86 | 2019-2020 | |
| Celltrion USA INC. | $51.77 | 2024 | Zymfentra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $44.91 | 2023 | Idacio |
| Nestle Healthcare Nutrition INC. | $44.86 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $34.88 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $34.18 | 2024 | Omvoh |
| Alfasigma USA, INC. | $31.28 | 2020 | |
| Phathom Pharmaceuticals, INC. | $30.45 | 2025 | Voquezna |
| Medtronic, INC. | $30.04 | 2023 | Gi Genius |
| Amgen INC. | $26.60 | 2021 | |
| Merck Sharp & Dohme LLC | $26.54 | 2020-2021 | |
| Ardelyx, INC. | $20.41 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $19.68 | 2023 | Fujifilm |
| Stryker Corporation | $19.06 | 2025 | Neptune |
| Endo Pharmaceuticals INC. | $16.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.